Other than the small sample size of this pilot study, this observation may be explained by the fact that, although the standard dose of PG used for adult patients with chronic hepatitis B is generally 30 mg/d,14 this dose may be insufficient to inhibit CCR2 in the context of diabetes in humans. The gene discussed is CCR2; the disease is diabetes mellitus.